<DOC>
	<DOC>NCT01874678</DOC>
	<brief_summary>Objectives: 1. Primary Objective: To bridge the data of efficacy in term of overall response rate of TS-1 plus cisplatin in Taiwanese advanced NSCLC patients from that gained from Japanese population 2. Secondary Objectives: A. To assess progression free survival B. To assess overall survival C. To bridge the safety profile by assessing the toxicities and tolerability</brief_summary>
	<brief_title>A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>To be eligible for inclusion, each subject must fulfill all of the following criteria: 1. histologically or cytologically confirmed nonsmall cell bronchogenic carcinoma 2. Stage IIIb or IV disease 3. presence of at least one measurable disease which is defined as lesion that can be measured in at least 1 dimension as ≥20 mm with conventional CT/MRI or ≥10 mm with spiral CT scan 4. performance status of ECOG 0, 1 5. age between 20 and 74 years at registration 6. life expectancy of at least 12 weeks 7. ability to take the oral study medication (TS1) 8. voluntarily signed the written informed consent form. other malignancy with the exception of curative treated nonmelanoma skin cancer or cervical carcinoma in situ within 5 years prior to the entry of study previously received chemotherapy or therapy with systemic antitumor effect significant comorbid medical conditions, including, but not limited to , heart failure, renal failure, hepatic failure, hemorrhagic peptic ulcer, mechanical or paralytic ileus, or poorly controlled diabetes fertile women of childbearing potential unless using a reliable and appropriate contraceptive method throughout the treatment period and for three months following cessation of treatment Presence of mental disease or psychotic manifestation Participation in another clinical trial with any investigational drug within 30 days prior to entry judged ineligible by physicians for participation in the study due to safety concern.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>